Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk factors for poor response to denosumab treatment in Japanese postmenopausal women with osteoporosis

Published:2022-08-08 Issue:6 Volume:40 Page:960-967
ISSN:0914-8779
Container-title:Journal of Bone and Mineral Metabolism
language:en
Short-container-title:J Bone Miner Metab

Author:

Okawa Tokutaro^ORCID,Okawa Motomi^ORCID,Koike Tatsuya^ORCID

Funder

AbbVie

Astellas Pharma

Bristol-Myers Squibb

Chugai Pharmaceutical

Daiichi-Sankyo

Eisai

Eli Lilly Japan

Mitsubishi Tanabe Pharma Corporation

MSD K.K.

Ono Pharmaceutical

Pfizer

Rochester Academy of Science

Takeda Pharmaceutical Company

Teijin Pharma

UCB US

Publisher

Springer Science and Business Media LLC

Subject

Endocrinology,Orthopedics and Sports Medicine,General Medicine,Endocrinology, Diabetes and Metabolism

Link

https://link.springer.com/content/pdf/10.1007/s00774-022-01357-z.pdf

Reference38 articles.

1. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287

2. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2010) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporos Int 21:1943–1951

3. Sampalis JS, Adachi JD, Rampakakis E, Vaillancourt J, Karellis A, Kindundu C (2012) Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence. J Bone Miner Res 27:202–210

4. McClung MR, Lewiecki EM, Cohen SB, Bolognese GC, Woodson AH et al (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821–831

5. Kamimura M, Nakamura Y, Ikegami S, Uchiyama S, Kato H, Taguchi A (2017) Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients. Osteoporos Int 28:559–566

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk factors for nonresponse to 2 years of denosumab administration in patients with osteoporosis: A retrospective single‐center cohorts study;Health Science Reports;2024-04

2. Zinc improves Denosumab and eldecalcitol efficacy for bone mineral density in patients with hypozincemia;Journal of Bone and Mineral Metabolism;2024-02-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3